| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -26,464 | -17,111 |
| Stock-based compensation expense | 4,846 | 4,045 |
| Net accretion of discount on investments | 953 | 742 |
| Prepaid expenses and other assets | -1,353 | 1,160 |
| Accounts payable | -1,091 | -1,204 |
| Accrued compensation | 68 | -477 |
| Accrued liabilities | -1,749 | -1,500 |
| Other current liabilities | -608 | -74 |
| Net cash used in operating activities | -24,598 | -18,223 |
| Purchases of investments | 37,863 | 33,973 |
| Maturities of investments | 59,000 | 49,000 |
| Net cash provided by investing activities | 21,137 | 15,027 |
| Proceeds from issuance of common stock under the espp | 86 | 38 |
| Proceeds from exercise of stock options | 27 | 27 |
| Net cash provided by financing activities | 113 | 65 |
| Net (decrease) increase in cash and cash equivalents | -3,348 | -3,131 |
| Cash and cash equivalents at beginning of period | 21,351 | - |
| Cash and cash equivalents at end of period | 18,003 | - |
AN2 Therapeutics, Inc. (ANTX)
AN2 Therapeutics, Inc. (ANTX)